Oslo, Norway, April 29, 2025 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced the publication of the
Annual Report for 2024. 

The Board of Directors of Nykode Therapeutics ASA has approved the annual
accounts for 2024. The financial statements and annual report for the financial
year 2024 are attached in European Single Electronic Format (ESEF) and as a PDF
file. 

The documents are also available in the investors section of the Company's
website: https://nykode.com/investors/financial-reports/
 
 
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.
 
Nykode's lead product candidates are VB10.16, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of cervical
cancer. VB10.16 is currently being further developed in head and neck cancer.
VB10.NEO, an individualized cancer neoantigen immunotherapy, has been
investigated in 2 trials with more than 10 different indications. 
 
Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.
 
Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA 
IR@nykode.com
 
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

This information is subject to the disclosure requirements pursuant to sections
5-12 of the Norwegian Securities Trading Act.